1. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol 2011; 204: 193-201. [
DOI:10.1016/j.ajog.2010.08.009]
2. Romero R, Kusanovic JP, Chaiworapongsa T, Hassan SS. Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. Best Pract Res Clin Obstet Gynaecol 2011; 25: 313-327. [
DOI:10.1016/j.bpobgyn.2011.02.006]
3. Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag 2011; 7: 467-474. [
DOI:10.2147/VHRM.S20181]
4. Can M, Guven B, Bektas S, Arikan I. Oxidative stress and apoptosis in preeclampsia. Tissue Cell 2014; 46: 477-481. [
DOI:10.1016/j.tice.2014.08.004]
5. Tomas SZ, Prusac IK, Roje D, Tadin I. Trophoblast apoptosis in placentas from pregnancies complicated by preeclampsia. Gynecol Obstet Invest 2011; 71: 250-255. [
DOI:10.1159/000320289]
6. Barakonyi A, Miko E, Szereday L, Polgar PD, Nemeth T, Szekeres-Bartho J, et al. Cell death mechanisms and potentially cytotoxic natural immune cells in human pregnancies complicated by preeclampsia. Reprod Sci 2014; 21: 155-166. [
DOI:10.1177/1933719113497288]
7. Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003; 23: 1553-1558. [
DOI:10.1161/01.ATV.0000086961.44581.B7]
8. Cackovic M, Buhimschi CS, Zhao G, Funai EF, Norwitz ER, Kuczynski E, et al. Fractional excretion of tumor necrosis factor-alpha in women with severe preeclampsia. Obstet Gynecol 2008; 112: 93-100. [
DOI:10.1097/AOG.0b013e31817c4304]
9. Zhou P, Luo X, Qi HB, Zong WJ, Zhang H, Liu DD, et al. The expression of pentraxin 3 and tumor necrosis factor-alpha is increased in preeclamptic placental tissue and maternal serum. Inflamm Res 2012; 61: 1005-1012. [
DOI:10.1007/s00011-012-0507-x]
10. Smith SD, Dunk CE, Aplin JD, Harris LK, Jones RL. Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy. Am J Pathol 2009; 174: 1959-1971. [
DOI:10.2353/ajpath.2009.080995]
11. Mihu D, Razvan C, Malutan A, Mihaela C. Evaluation of maternal systemic inflammatory response in preeclampsia. Taiwan J Obstet Gynecol 2015; 54: 160-166. [
DOI:10.1016/j.tjog.2014.03.006]
12. Germain SJ, Sacks GP, Soorana SR, Sargent IL, Redman CW. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007; 178: 5949-5956. [
DOI:10.4049/jimmunol.178.9.5949]
13. Kauma SW, Huff TF, Hayes N, Nilkaeo A. Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus. J Clin Endocrinol Metab 1999; 84: 2188-2194. [
DOI:10.1210/jc.84.6.2188]
14. Resic Karara J, Zekic Tomas S, Marusic J, Roje D, Kuzmic Prusac I. Fas and FasL expression in placentas complicated with intrauterine growth retardation with and without preeclampsia. J Matern Fetal Neonatal Med 2016; 29: 1154-1159. [
DOI:10.3109/14767058.2015.1038702]
15. Prusac IK, Zekic Tomas S, Roje D. Apoptosis, proliferation and Fas ligand expression in placental trophoblast from pregnancies complicated by HELLP syndrome or pre-eclampsia. Acta Obstet Gynecol Scand 2011; 90: 1157-1163. [
DOI:10.1111/j.1600-0412.2011.01152.x]
16. Martinez-Fierro ML, Garza-Veloz I, Carrillo-Sanchez K, Martinez-Gaytan V, Cortes-Flores R, Ochoa-Torres MA, et al. Expression levels of seven candidate genes in human peripheral blood mononuclear cells and their association with preeclampsia. Hypertens Pregnancy 2014; 33: 191-203. [
DOI:10.3109/10641955.2013.853777]
17. Chen G, Wilson R, Wang SH, Zheng HZ, Walker JJ, McKillop JH. Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol 1996; 104: 154-159. [
DOI:10.1046/j.1365-2249.1996.d01-647.x]
18. Nishizawa H, Ota S, Suzuki M, Kato T, Sekiya T, Kurahashi H, et al. Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod Biol Endocrinol 2011; 9: 107-118. [
DOI:10.1186/1477-7827-9-107]
19. Barakonyi A, Miko E, Szereday L, Polgar PD, Nemeth T, Szekeres-Bartho J, et al. Cell death mechanisms and potentially cytotoxic natural immune cells in human pregnancies complicated by preeclampsia. Reprod Sci 2014; 21: 155-166. [
DOI:10.1177/1933719113497288]
20. Kuntz TB, Christensen RD, Stegner J, Duff P, Koenig JM. Fas and Fas ligand expression in maternal blood and in umbilical cord blood in preeclampsia. Pediatr Res 2001; 50: 743-749. [
DOI:10.1203/00006450-200112000-00019]
21. Bränn E, Edvinsson Å, Rostedt Punga A, Sundström-Poromaa I, Skalkidou A. Inflammatory and anti-inflammatory markers in plasma: from late pregnancy to early postpartum. Sci Rep 2019; 9: 1863-1872. [
DOI:10.1038/s41598-018-38304-w]
22. Raghupathy R. Cytokines as key players in the pathophysiology of preeclampsia. Med Princ Pract 2013; 22 (Suppl.): 8-19. [
DOI:10.1159/000354200]
23. Pinheiro MB, Martins-Filho OA, Mota AP, Alpoim PN, Godoi LC, Silveira AC, et al. Severe preeclampsia goes along with a cytokine network disturbance towards a systemic inflammatory state. Cytokine 2013; 62: 165-173. [
DOI:10.1016/j.cyto.2013.02.027]
24. Perucci LO, Gomes KB, Freitas LG, Godoi LC, Alpoim PN, Pinheiro MB, et al. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PloS One 2014; 9: e97632. [
DOI:10.1371/journal.pone.0097632]
25. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 2001; 86: 2505-2512. [
DOI:10.1210/jc.86.6.2505]
26. Slungaard A, Vercellotti GM, Walker G, Nelson RD, Jacob HS. Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med 1990; 171: 2025-2041. [
DOI:10.1084/jem.171.6.2025]
27. Fluhr H, Krenzer S, Stein GM, Stork B, Deperschmidt M, Wallwiener D, et al. Interferon-γ and tumor necrosis factor-α sensitize primarily resistant human endometrial stromal cells to Fas-mediated apoptosis. J Cell Sci 2007; 120: 4126-4133. [
DOI:10.1242/jcs.009761]
28. Aschkenazi S, Straszewski S, Verwer KM, Foellmer H, Rutherford T, Mor G. Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells. Biol Reprod 2002; 66: 1853-1861. [
DOI:10.1095/biolreprod66.6.1853]
29. Neale D, Demasio K, Illuzi J, Chaiworapongsa T, Romero R, Mor G. Maternal serum of women with pre-eclampsia reduces trophoblast cell viability: evidence for an increased sensitivity to Fas-mediated apoptosis. J Matern Fetal Neonatal Med 2003; 13: 39-44. [
DOI:10.1080/jmf.13.1.39.44]
30. Dagdelen M, Temur M, Yılmaz Ö, Altındag T, Uslu T, Özbay PÖ. Placental bed apoptosis is increased in pregnant women with pre-eclampsia versus normotensive pregnant women. J Obstet Gynaecol 2016; 36: 974-979. [
DOI:10.1080/01443615.2016.1178221]
31. Mendilcioglu I, Karaveli S, Erdogan G, Simsek M, Taskin O, Ozekinci M. Apoptosis and expression of Bcl-2, Bax, p53, caspase-3, and Fas, Fas ligand in placentas complicated by preeclampsia. Clin Exp Obstet Gynecol 2011; 38: 38-42.
32. Longtine MS, Chen B, Odibo AO, Zhong Y, Nelson DM. Villous trophoblast apoptosis is elevated and restricted to cytotrophoblasts in pregnancies complicated by preeclampsia, IUGR, or preeclampsia with IUGR. Placenta 2012; 33: 352-359. [
DOI:10.1016/j.placenta.2012.01.017]